Korea’s MEDITIP and CIRPE, Ministry of Trade, Industry & Energy (MOTIE), awards clinivation FY 2014 funding to support global strategic partnering in biopharmaceuticals.
NATICK, MA – May 30, 2014 – Clinivation, Inc., a leading provider of life sciences solutions that deliver the digital advantage to outperform in global development and commercialization, announced today that today that it has executed an industrial master agreement comprising the MEDITIP-CIRPE-MOTIE initiative for global strategic partnering of their biopharmaceutical portfolio.
Specific aims of the agreement include advancing certain portfolio and business development initiatives with global leaders in the pharmaceutical and biotechnology industries. As part of this agreement, clinivation Founder and CEO Joseph Kozikowski, M.D. will represent CIRPE as Director, Global Strategic Partnering, CIRPE.
Quotes & Commentary:
“It is an honor and my pleasure to support and work with Drs. Kyeoung-Mi Lee, Hak-Sung Lee, JeoungHee Yoo, and participants from the Ministry, government, and industry in this important initiative,” said Joseph Kozikowski, M.D., clinivation Founder and CEO. “I believe Korea’s successful track record of growth and innovation in life sciences will continue, because of the vision and commitment of its highly-capable leaders, Korea’s modern, excellent infrastructure, and the brilliant insights of Korea’s innovators,” he continued.
Supporting Resources:
For more information on the clinivation Prospectus Platform for Connected Therapeutic Area Strategy, please visit the clinivation Prospectus homepage.
About CIRPE:
The Chungcheong Institute for Regional Program Evaluation (CIRPE) for the Chungcheong economic region is an organization funded by the Ministry of Trade, Industry & Energy (MOTIE) of Korea. Chungcheong economic region, the center of development of new drugs in Korea, has been growing with 20 advanced pharmaceuticals groups and 100 state-of-the-art pharmaceutical companies.
Goals for the CIRPE Bio Medicine Division are to develop 20 new drugs and reach up to 2.0% of the global market-share by nourishing 20 new pharmaceutical manufacturers by 2020. These goals are intended to contribute to the Chungcheong area, so that it can be positioned as a core base for domestic new drug development. The portfolio of selected projects includes small molecules, biologics, biomedical raw materials, and pharmaceuticals for animal health.
